

Moderator: Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium

The data presented will refer to the following studies:

[Navigation überspringen](#)

[Friday, 26 September 2014 - Cross-comparison of cancer drug approvals among international regulatory bodies - Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA](#)

[Saturday, 27 September 2014 Cancer during pregnancy: children prenatally exposed to CT - primary efficacy results of LUX-head & neck 1, a phase III trial \(Afatinib\) - results from the Phase 3 studies ROMANA 1 and 2 \(Anamorelin\) - Phase 3 \(P04832\) trial results for rolapitant](#)

[Frédéric Amant, University of Leuven, Leuven, Belgium Cancer during pregnancy: A case-control analysis of mental development and cardiac functioning of 38 children prenatally exposed to chemotherapy](#)

[Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium Afatinib versus methotrexate \(MTX\) as second-line treatment for patients with recurrent and/or metastatic \(R/M\) head and neck squamous cell carcinoma \(HNSCC\) who progressed after platinum-based therapy: primary efficacy results of LUX-head & neck 1, a pha](#)

[David Currow, Flinders University, Adelaide, Australia Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: results from the Phase 3 studies ROMANA 1 and 2](#)

[Bernardo Leon Rapoport, The Medical Oncology Centre – Rosebank, Johannesburg, South Africa Phase 3 \(P04832\) trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting \(CINV\) in subjects receiving cisplatin-based chemotherapy](#)

Sunday, 28 September 2014 The IMPRESS study (Gefitinib) - Final OS analysis from CLEOPATRA – MAGRIT: efficacy of the recMAGE-A3+ AS15 cancer immunotherapeutic in resected MAGE-A3+ NSCLC - CIRCCa: carboplatin-paclitaxel with/without cediranib in metastatic/recurrent cervical cancer

Tony Mok, The Chinese University of Hong Kong, Shatin, China LBA2 Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the Phase III, randomised IMPRESS study

Sandra Swain, Washington Cancer Institute, Washington, United States 3500 Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

Johan F. Vansteenkiste, University Hospitals Leuven – Campus Gasthuisberg, Leuven, Belgium 11730 MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC)

Raymond Symonds, University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, United Kingdom LBA25 CIRCCa: A randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. (CRUK Grant Ref: C1256/A11416)

Monday, 29 September 2014 Melanoma: - nivolumab vs. CT - Vemurafenib +/- Cobimetinib in Untreated BRAFV600 Mutation - COMBI-v: dabrafenib + trametinib vs. vemurafenib in BRAF V600E/K + - Neoadjuvant CT and extrapleural pneumonectomy of MPM) +/- hemithoracic radiotherapy: SAKK17/04

Grant McArthur, Peter MacCallum Cancer Centre, Melbourne, Australia LBA5 Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (NCT01689519)

[Jeffrey Weber, H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States LBA3 A phase 3 randomized, open-label study of nivolumab \(anti-PD-1; BMS-936558; ONO-4538\) versus investigator's choice chemotherapy \(ICC\) in patients with advanced melanoma after prior anti-CTLA-4 therapy](#)

[Caroline Robert, Gustave Roussy, Villejuif, France LBA4 COMBI-v: A randomised, open-label, Phase III study comparing the combination of dabrafenib and trametinib to vemurafenib as firstline therapy in patients \(pts\) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma](#)

[Rolf Stahel, Universitätsspital Zürich, Zürich, Switzerland LBA37 Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma \(MPM\) with or without hemithoracic radiotherapy: final results of the randomized multicenter phase II trial SAKK17/04](#)

[Tuesday, 30 September 2014 Top practice changes to implement after ESMO 2014 - The paradigm of precision medicine: reality or dream? - Congress figures take-home messages](#)

-